GALNT13 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL7980209	1.00	1/20
SCHEMBL29370098	1.00	1/20
SCHEMBL26768213	0.79	1/20
SCHEMBL7987277	0.69	1/20
SCHEMBL2357304	0.68	1/20
SCHEMBL29466713	0.68	1/20
SCHEMBL29827270	0.68	1/20
SCHEMBL17949557	0.66	1/20
SCHEMBL7984298	0.66	1/20
SCHEMBL9748319	0.61	1/20
SCHEMBL21517158	0.61	1/20
SCHEMBL3874869	0.61	1/20
SCHEMBL15285080	0.61	1/20
SCHEMBL31414410	0.61	1/20
SCHEMBL7330918	0.60	1/20
SCHEMBL22431062	0.59	1/20
SCHEMBL1444851	0.58	1/20
SCHEMBL30451609	0.58	1/20
SCHEMBL5351976	0.58	1/20
SCHEMBL7227954	0.57	1/20

Clinical trials — most relevant to GALNT13 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease	PHASE4	COMPLETED
Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease	PHASE3	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
Multi-Center Study of ManNAc for GNE Myopathy	PHASE2	ACTIVE_NOT_RECRUITING
A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA	PHASE1/PHASE2	COMPLETED
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Study of GlcNAc on Tear Production in NGLY1-CDDG	PHASE2	ACTIVE_NOT_RECRUITING
Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease	PHASE1/PHASE2	SUSPENDED
An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy	PHASE2	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects	PHASE1	UNKNOWN
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
BMN 110 US Expanded Access Program	nan	APPROVED_FOR_MARKETING
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Screening of Fabry Disease in Patients With GI Symptoms	nan	UNKNOWN
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease	nan	RECRUITING
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease	nan	RECRUITING
Early Detection and Follow-Up of Patients With Fabry's Disease	nan	UNKNOWN
Sialic Acid Supplementation in N-Acetylneuraminic Acid Synthase (NANS) Deficiency	nan	COMPLETED
Evaluation of Blood Protein O-GlcNAcylation Levels in Children	nan	RECRUITING
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Registry Gangliosidoses	nan	UNKNOWN
A Prospective Trial to Identify Biomarkers Involved in the Transition From Acute to Persistent Chronic Low Back Pain	nan	UNKNOWN
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a GALNT13 binder may also engage these)

Protein	Name	Similarity
Q8CF93	—	1.000	Q8CF93 →
Q6UE39	—	1.000	Q6UE39 →
GALNT1	Polypeptide N-acetylgalactosaminyltransferase 1	1.000	landscape →
Q29121	—	1.000	Q29121 →
O08912	—	1.000	O08912 →
Q07537	—	1.000	Q07537 →
Q10473	—	1.000	Q10473 →
Q8BVG5	—	0.999	Q8BVG5 →
Q8MV48	—	0.999	Q8MV48 →
Q6WV17	—	0.998	Q6WV17 →
Q49A17	—	0.998	Q49A17 →
Q925R7	—	0.998	Q925R7 →
S5S833	—	0.997	S5S833 →
GALNT10	Polypeptide N-acetylgalactosaminyltransferase 10	0.997	landscape →
GALNT14	Polypeptide N-acetylgalactosaminyltransferase 14	0.996	landscape →
Q6PB93	—	0.996	Q6PB93 →
Q6P6V1	—	0.995	Q6P6V1 →
Q921L8	—	0.995	Q921L8 →
Q6DJR8	—	0.995	Q6DJR8 →
GALNT3	Polypeptide N-acetylgalactosaminyltransferase 3	0.995	landscape →
Q9JJ61	—	0.994	Q9JJ61 →
Q8C7U7	—	0.994	Q8C7U7 →
Q8IXK2	—	0.994	Q8IXK2 →
Q6WV19	—	0.994	Q6WV19 →
Q5EA41	—	0.994	Q5EA41 →
Q9D4M9	—	0.993	Q9D4M9 →
Q5RFJ6	—	0.993	Q5RFJ6 →
GALNT2	Polypeptide N-acetylgalactosaminyltransferase 2	0.993	landscape →
P70419	—	0.993	P70419 →
Q6WV16	—	0.993	Q6WV16 →